Energy restriction as an antitumor target. (Q51773654)

12 April 2018

editorial

0 references

title

Energy restriction as an antitumor target. (English)

1 reference

12 April 2018

author

Hany A. Omar

1

1 reference

12 April 2018

author name string

Lisa Berman-Booty

2

1 reference

12 April 2018

Samuel K Kulp

3

1 reference

12 April 2018

Ching-Shih Chen

4

1 reference

12 April 2018

language of work or name

English

0 references

publication date

1 November 2010

1 reference

12 April 2018

published in

Future Oncology

1 reference

12 April 2018

volume

6

1 reference

12 April 2018

issue

11

1 reference

12 April 2018

page(s)

1675-1679

1 reference

12 April 2018

Cancer cell metabolism: Warburg and beyond

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Q&A: Cancer: clues from cell metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Cancer's molecular sweet tooth and the Warburg effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Tumor cell metabolism: cancer's Achilles' heel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Cancer as a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

The Warburg Effect returns to the cancer stage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

c-Myc target genes involved in cell growth, apoptosis, and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Akt stimulates aerobic glycolysis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Energy boost: the Warburg effect returns in a new theory of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Glucose up-regulates HIF-1 alpha expression in primary cortical neurons in response to hypoxia through maintaining cellular redox status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Mitochondrial superoxide dismutase: a promising target for new anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Altered redox status accompanies progression to metastatic human bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Understanding the Warburg effect: the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Clinical aspects of the ketogenic diet

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Therapeutic potential of resveratrol: the in vivo evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Resveratrol: from basic science to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Energy restriction as an antitumor target of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Cancer chemopreventive activity of resveratrol, a natural product derived from grapes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Resveratrol: a review of preclinical studies for human cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

The Warburg effect and its cancer therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

The effects of 2-deoxy-D-glucose on metabolism of slices of cerebral cortex incubated in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Metabolic approaches to treatment of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

ATP citrate lyase inhibition can suppress tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.130

21 January 2018

Identifiers

DOI

10.2217/FON.10.130

1 reference

12 April 2018

release_7xol3s5lsjd2ralo7xllrfcpp4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7xol3s5lsjd2ralo7xllrfcpp4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

21142654

1 reference

12 April 2018